Brief: Argenx Says CHMP Recommends EC Approval Of VYVGART For CIDP
28/04/2025 06:03
April 28 (Reuters) - argenx SE ARGX.BR: ANNOUNCES POSITIVE CHMP (COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE) OPINION FOR VYVGART (EFGARTIGIMOD ALFA) SUBCUTANEOUS INJECTION FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) VYVGART IS FIRST TARGETED IGG FC-ANTIBODY FRAGMENT FOR CIDP ADHERE TRIAL SHOWS 66.5% CLINICAL IMPROVEMENT WITH VYVGART ADHERE TRIAL DEMONSTRATES 61% REDUCTION IN RELAPSE RISK EC DECISION ON VYVGART MARKETING AUTHORIZATION EXPECTED IN TWO MONTHS Source text: ID:nGNE8Ks99F Further company coverage: ARGX.BR (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on argenx SE
See all newsArgenx falls after Vyvgart trial update on myositis drug, brokers remain positive
Brief: ArgenX Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit In Myositis And Sjogren’S Disease
Brief: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Brief: Argenx Q1 Total Operating Income USD 1.313 Bln
Netherlands' Argenx Q1 net sales rise 63%, profit more than doubles